Misonix Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Misonix, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MSON

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Misonix, Inc. (NASDAQ: MSON) to Bioventus Inc. is fair to Misonix shareholders. Under the terms of the agreement, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration.

Halper Sadeh encourages Misonix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Misonix and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Misonix shareholders; (2) determine whether Bioventus is underpaying for Misonix; and (3) disclose all material information necessary for Misonix shareholders to adequately assess and value the merger consideration. On behalf of Misonix shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Misonix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210729006212/en/